Telomir制药公司报告说,可以治疗威尔逊病的新化合物有良好的结果,这是一种罕见的铜毒性紊乱症。 Telomir Pharmaceuticals reports promising results for a new compound that could treat Wilson's disease, a rare copper toxicity disorder.

Telomir制药公司报告说,Telomir-1的临床预科结果很有希望,这是对Wilson病的潜在治疗,是一种罕见的疾病,导致有毒铜积聚。 Telomir Pharmaceuticals has reported promising preclinical results for Telomir-1, a potential treatment for Wilson's disease, a rare disorder causing toxic copper buildup. 该化合物显示出高铜合金的亲和性,与目前的选择相比,这可能导致更有效和更安全的治疗。 The compound shows high copper-binding affinity, which could lead to a more effective and safer therapy compared to current options. Telomir计划在2026年中期开始人类试验,并正在探索Telomir-1在治疗2型糖尿病和与年龄有关的疾病方面的用途。 Telomir plans to begin human trials by mid-2026 and is also exploring Telomir-1's use in treating type 2 diabetes and age-related diseases.